Skip to content
Disclosery

EXANE DERIVATIVES: CRNC position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on CRNC, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 31 CRNC shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 31 shares
    Change vs previous 13F -1,519 shares

    <0.01% of the 13F portfolio, value $782.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 1,550 shares
    Change vs previous 13F -229 shares

    0.02% of the 13F portfolio, value $55,952.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 1,779 shares
    Change vs previous 13F -502 shares

    0.03% of the 13F portfolio, value $136,338.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 2,281 shares
    Change vs previous 13F -441 shares

    0.05% of the 13F portfolio, value $219,219.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 2,722 shares
    Change vs previous 13F +123 shares

    0.07% of the 13F portfolio, value $307,770.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 2,599 shares
    Change vs previous 13F not available

    0.07% of the 13F portfolio, value $232,808.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).